Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Otsuka
Biotech
Otsuka heads to FDA as Ionis-allied ALS drug hits primary goal
A phase 3 study of Otsuka and Ionis’ ALS prospect hit its primary endpoint, positioning the partners to talk to regulators about expedited approvals.
Nick Paul Taylor
Sep 22, 2026 9:22am
Otsuka posts phase 3b ADHD trial win ahead of looming FDA ruling
Jun 25, 2026 9:13am
Japan biotech inks RNA research pact that includes mRNA compounds
Sep 19, 2025 10:49am
Otsuka inks $613M deal for Swedish biotech's IL1RAP antibodies
Jul 16, 2025 1:37pm
Otsuka gives cancer candidates the kiss-off on strategic grounds
Feb 14, 2025 5:30am
FDA clears Otsuka, Click's prescription app for depression
Apr 3, 2024 1:53pm